Aglaia Oncology Funds invests in early-stage oncology drug development companies with breakthrough inventions that have the potential to transform cancer treatment. They focus on selecting and maturing these early-stage ventures, de-risking them and making them attractive candidates for licensing, acquisition, or IPO. Aglaia is committed to defining the strategic directions of the companies it invests in in close collaboration with innovators and entrepreneurs. Since 2004, Aglaia has built a reputation for starting up biotech companies focused on oncology drug development. They bring hands-on experience in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies. The Aglaia team has decades of experience in cancer research and oncology drug development. Aglaia's continuous strategic and operational involvement with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companies to clinical-stage companies. Six of the 12 companies they've invested in were founded by Aglaia.
Preferred startup development maturity for initial funding deployment.
Oncology drug development
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...